Dhea
Postmenopausal Atrophic Vaginitis
Hadassah Medical OrganizationUNKNOWNPhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Postmenopausal Atrophic Vaginitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dehydroepiandrosterone University Hospital, Ghent | Phase 4 | BB |
Pilocarpinum Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Estriol ITF Research Pharma, S.L.U. | Phase 2 | BB |
Autologous Conditioned Plasma University of Miami | Phase 2 | B |
Polycarbophil University of Arkansas | Phase 2 | CCC |
Testosterone Undecylate Creighton University | Early Phase 1 | CC |
Promestriene Federal University of São Paulo | N/A | D |
Same molecule, other indications
Dhea is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →